Literature DB >> 20172038

Second unrelated donor hematopoietic cell transplantation for primary graft failure.

Jeffrey Schriber1, Manza-A Agovi, Vincent Ho, Karen K Ballen, Andrea Bacigalupo, Hillard M Lazarus, Christopher N Bredeson, Vikas Gupta, Richard T Maziarz, Gregory A Hale, Mark R Litzow, Brent Logan, Martin Bornhauser, Roger H Giller, Luis Isola, David I Marks, J Douglas Rizzo, Marcelo C Pasquini.   

Abstract

Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell transplantation (HCT). We describe the results of 122 patients reported to the National Marrow Donor Program between 1990 and 2005, who received a second unrelated donor HCT after failing to achieve an absolute neutrophil count of >or=500/microL without recurrent disease. Patients were transplanted for leukemia (n = 83), myelodysplastic disorders (n = 16), severe aplastic anemia (n = 20), and other diseases (n = 3). The median age was 29 years. Twenty-four patients received second grafts from a different unrelated donor. Among 98 patients who received a second graft from the same donor, 28 received products that were previously collected and cryopreserved for the first transplantation. One-year overall survival (OS) after second transplant was 11%, with 10 patients alive at last follow-up. We observed no differences between patients who received grafts from the same or different donors, or in those who received fresh or cryopreserved product. The outcomes after a second allogeneic HCT for primary graft failure are dismal. Identifying risk factors for primary graft failure can decrease the incidence of this complication. Further studies are needed to test whether early recognition and hastened procurement of alternative grafts can improve transplant outcomes for primary graft failure.

Entities:  

Mesh:

Year:  2010        PMID: 20172038      PMCID: PMC2897953          DOI: 10.1016/j.bbmt.2010.02.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

1.  Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation.

Authors:  P Guardiola; M Kuentz; F Garban; D Blaise; J Reiffers; M Attal; A Buzyn; B Lioure; P Bordigoni; N Fegueux; M L Tanguy; J P Vernant; E Gluckman; G Socié
Journal:  Br J Haematol       Date:  2000-10       Impact factor: 6.998

Review 2.  Changing trends in marrow transplantation for aplastic anemia.

Authors:  R Storb; G Longton; C Anasetti; F R Appelbaum; P Beatty; W Bensinger; S Crawford; H J Deeg; K Doney; A Fefer
Journal:  Bone Marrow Transplant       Date:  1992       Impact factor: 5.483

3.  Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts.

Authors:  J Mehta; R Powles; S Singhal; C Horton; G Middleton; T Eisen; S Meller; C R Pinkerton; J Treleaven
Journal:  Bone Marrow Transplant       Date:  1997-02       Impact factor: 5.483

4.  Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation.

Authors:  J Nemunaitis; J W Singer; C D Buckner; D Durnam; C Epstein; R Hill; R Storb; E D Thomas; F R Appelbaum
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

5.  Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation.

Authors:  V L Grandage; J M Cornish; D H Pamphilon; M N Potter; C G Steward; A Oakhill; D I Marks
Journal:  Bone Marrow Transplant       Date:  1998-04       Impact factor: 5.483

6.  Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony-stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte-CSF.

Authors:  D J Weisdorf; C M Verfaillie; S M Davies; A H Filipovich; J E Wagner; J S Miller; J Burroughs; N K Ramsay; J H Kersey; P B McGlave
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

7.  Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group.

Authors:  S R McCann; A Bacigalupo; E Gluckman; W Hinterberger; J Hows; P Ljungman; P Marin; C Nissen; E van't Veer Kerthof; A Raghavachar
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

8.  Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results.

Authors:  R E Champlin; M M Horowitz; D W van Bekkum; B M Camitta; G E Elfenbein; R P Gale; E Gluckman; R A Good; A A Rimm; C Rozman
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

Review 9.  Second hematopoietic stem cell transplantation in myeloid malignancies.

Authors:  Lisa M Arfons; Marcie Tomblyn; Vanderson Rocha; Hillard M Lazarus
Journal:  Curr Opin Hematol       Date:  2009-03       Impact factor: 3.284

10.  Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation.

Authors:  M Remberger; O Ringdén; P Ljungman; H Hägglund; J Winiarski; B Lönnqvist; J Aschan
Journal:  Bone Marrow Transplant       Date:  1998-07       Impact factor: 5.483

View more
  16 in total

1.  Poor graft function can be durably and safely improved by CD34+-selected stem cell boosts after allogeneic unrelated matched or mismatched hematopoietic cell transplantation.

Authors:  Sebastian P Haen; Michael Schumm; Christoph Faul; Lothar Kanz; Wolfgang A Bethge; Wichard Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-14       Impact factor: 4.553

2.  Uric acid as a novel biomarker for bone-marrow function and incipient hematopoietic reconstitution after aplasia in patients with hematologic malignancies.

Authors:  Sebastian P Haen; Vicky Eyb; Nora Mirza; Aline Naumann; Andreas Peter; Markus W Löffler; Christoph Faul; Wichard Vogel; Wolfgang A Bethge; Hans-Georg Rammensee; Lothar Kanz; Martin Heni
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-16       Impact factor: 4.553

3.  The number of CD34+CD133+ hematopoietic stem cells residing in umbilical cord blood (UCB) units is not correlated with the numbers of total nucleated cells and CD34+ cells: a possible new indicator for quality evaluation of UCB units.

Authors:  Yoshikazu Matsuoka; Fumiaki Nakamura; Kazuo Hatanaka; Tatsuya Fujioka; Satoshi Otani; Takafumi Kimura; Yoshihiro Fujimura; Hiroaki Asano; Yoshiaki Sonoda
Journal:  Int J Hematol       Date:  2018-07-25       Impact factor: 2.490

4.  Treatment of poor graft function after allogeneic hematopoietic cell transplantation with a booster of CD34-selected cells infused without conditioning.

Authors:  B Askaa; A Fischer-Nielsen; L Vindeløv; E K Haastrup; H Sengeløv
Journal:  Bone Marrow Transplant       Date:  2014-02-03       Impact factor: 5.483

5.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

6.  Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft.

Authors:  N Epperla; M Pasquini; K Pierce; W R Drobyski; J D Rizzo; M M Horowitz; W Saber; K Zellner; S Ramirez; K Bartz; R V Raj; P N Hari; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2016-08-01       Impact factor: 5.483

7.  Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failure.

Authors:  H Aboul Nour; N Patil; J H Chewning; A Di Stasi; D Salzman; R Innis-Shelton; L Lamb; S Mineishi; A Saad
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

8.  Non-myeloablative conditioning for second hematopoietic cell transplantation for graft failure in patients with non-malignant disorders: a prospective study and review of the literature.

Authors:  K Mallhi; P J Orchard; W P Miller; Q Cao; J Tolar; T C Lund
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

9.  Second allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failure.

Authors:  Troy C Lund; Jessica Liegel; Nelli Bejanyan; Paul J Orchard; Qing Cao; Jakub Tolar; Claudio Brunstein; John E Wagner; Michael R Verneris; Daniel Weisdorf
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

10.  Subsequent donation requests among 2472 unrelated hematopoietic progenitor cell donors are associated with bone marrow harvest.

Authors:  Robert N Lown; Sameer Tulpule; Nigel H Russell; Charles F Craddock; Rochelle Roest; J Alejandro Madrigal; Bronwen E Shaw
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.